| poly ADP-ribose polymerase (PARP) inhibitor |
| veliparib plus paclitaxel plus carboplatin |
| mBC - Triple negative (TNBC) - 1st Line (L1) 1 | |
| mBC - TNBC - L1 - all population 7 | |
| mBC - TNBC - L1 - PDL1 positive 4 | |
Comparator:
vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;